The dynamics of host-virus interactions, and impairment of the host's immune surveillance
by dengue virus (DENV) serotypes largely remain ambiguous. Several experimental and …

Immunoregulatory B cells impede antitumor immunity through unknown features and
mechanisms. We report the existence of leucine-tRNA-synthetase-2 (LARS2)-expressing B …

Dengue and Zika are arthropod-borne viral diseases present in more than 100 countries
around the world. In the past decade, Zika emerged causing widespread outbreaks in new …

Sequential dengue virus (DENV) infections often generate neutralizing antibodies against
all four DENV serotypes and sometimes, Zika virus. Characterizing cross-flavivirus broadly …

Heterotypic secondary dengue virus (DENV) infection is a risk factor for the development of
severe disease. To assess the contribution of the developing polyclonal humoral immune …

Dengue virus poses a serious threat to global health and there is no specific therapeutic for
it. Broadly neutralizing antibodies recognizing all serotypes may be an effective treatment …

Introduction B cells play an integral role in the immune response to both dengue fever and
COVID-19. Prior scRNAseq analyses of peripheral plasmablasts in COVID-19 have …

Dengue virus (DENV) is a prevalent human pathogen, infecting approximately 400 million
individuals per year and causing symptomatic disease in approximately 100 million. A …

Dengue human infection models present an opportunity to explore a vaccine, antiviral, or
immuno-compound's potential for clinical benefit in a controlled setting. Herein, we report …

Plasmablasts represent a specialized class of antibody-secreting effector B cells that
transiently appear in blood circulation following infection or vaccination. The expansion of …